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1. Introduction 
This chapter explains the foundations for permanent pacing and proposes a rational and 
critical approach about the indications for stimulation which are supported by current 
scientific evidence. We also review stimulation mode selection in different clinical scenarios, 
technical aspects of implantation, and outline a follow-up program for patients who carry 
stimulation devices.  
We consider convenient mentioning the initials used to designate the stimulation mode for 
pacemakers. The first letter refers to the paced chamber (could be 0=none, A=atrium, 
V=ventricle, D=dual), the second letter refers to the sensed chamber (could be 0=none, 
A=atrium, V=ventricle, D=dual), and the third letter to the type of response the pacemaker 
will have when detecting an intrinsic beat (could be 0=none, I=inhibitory, T=trigger, 
D=dual). There is a forth letter which confirms the presence of a sensor which modulates 
heart rate in to response physical activity (R=rate response). Thus, a VVI mode pacemaker 
paces and senses only the right ventricle, and it is inhibited if sensing an intrinsic beat. A 
DDD pacemaker paces and senses both chambers (right atrium and ventricle) and both 
leads can be inhibited by an intrinsic beat.  
2. Main clinical indications for pacing 
Cardiac stimulation through permanent pacing is a therapy that currently is clearly 
established for the treatment of patients with symptomatic bradycardia due to function 
alterations in the sinus and atrioventricular (AV) node. There are some indications in 
asymptomatic patients, which in general, are more controversial, with less scientific 
evidence in its favour.  
2.1 Sinus node dysfunction (SND) 
In 1923 Wenckebach described the electrocardiographic characteristics of SND, and in 1968 
Ferrer published the manifestations considering it as a clinical entity.1  
The node is formed, from a cytologic point of view, by P cells and transitional cells. P cells 
are responsible for the pacemaker function and present as groups of 3 or 4 cells. Transitional 
cells have two varieties: some connect P cells with the atria and the others form links 
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between the groups of P cells. Sinus node pacemaker activity is widely distributed and its 
automaticity is modulated by the autonomic function. Parasympathetic stimulation 
depresses automaticity and favors impulse propagation towards the lower part of the right 
atrium; on the contrary, sympathetic stimulation increases its automaticity and atrial 
activation starts in the upper part of the atrium.2  
The sinus node has a central portion responsible for the origin of the stimulus, and 
another which is peripheral, in charge of the conduction towards the atria; the last one is 
separated from the atrial myocardium by a band of connective tissue. Aging is associated 
with structural changes in the sinus node: increase in the amount of collagen, decrease in 
connexin (Cx43) expression, and possibly decrease in INa flow in the node periphery (the 
center of the node does not express that flow). 3 These alterations, either in the formation 
and/or propagation of the atrial impulse, condition a broad variety of presentations such 
as:  
• Persistent sinus bradycardia  
• Chronotropic incompetence without identifiable causes 
• Paroxysmal or persistent sinus arrest compensated by escape rhythms in the ventricular 
myocardium, in the AV junction and in some cases as paroxysmal or persistent atrial 
fibrillation (AF). 
The bradycardia-tachycardia syndrome is the association between sinus bradycardia and/or 
sinus arrest and AF.4 In this case tachycardia events depress node automatism by a 
suppression mechanism secondary to overstimulation. This way when tachycardia ceases 
abruptly, arrest or asystole supervene due to failure in the inferior pacemakers to rescue the 
heart rate. 5  
2.1.1 Epidemiology 
SND presents in the elderly, usually between the sixth and seventh decades of life.6,7 
Although it can present at any age as a secondary phenomenon due to any alteration that 
implies sinus node cell destruction, such as heart surgery, inflammation or ischemia. It 
conditions an annual complete AV block incidence of 0.6%, with 2.1% prevalence. 7,8  
2.1.2 Clinical ma ions  
Clinical manifestations are variable and can go from an asymptomatic stage, to subtle 
symptoms like dyspnea due to chronotropic incompetence (an inadequate response of heart 
rate to physical activity), to dizziness, to the most dramatic which is syncope. 9  
2.1.3 Diagnosis  
The following are tests which can be helpful to diagnose SND: 
• An electrocardiogram should be the initial test, although due to the briefness it may not 
completely correlate with the symptoms.  
• A treadmill test is useful to evaluate chronotropic response, it should be considered 
positive when the patient cannot reach 70% of the expected heart rate according to the 
age. 10 
• 24-hour holter monitoring is recommended when symptoms are regular; when the 
symptoms are sporadic an implantable loop recorder is an excellent alternative. 11 
Electrophysiological studies evaluate sinus function through two methods: 1) sinus node 
recovery time, which analyzes node automaticity after a suppression period after 
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overstimulation; 2) sinoatrial conduction time, which analyzes the conduction time to the 
sinus node and from the sinus node to the atrium as a response to atrial extrastimuli. 12  
2.1.4 Treatment  
For SND indications as for the rest of the chapter we refer to the classification of 
recommendations and level of evidence established by different cardiology societies. 
Currently the only effective method for the treatment of symptomatic SND is the 
implantation of a permanent pacemaker. See Table 1 for complete recommendations.  
 
Class I 
1. Is indicated for SND with documented symptomatic bradycardia, including frequent sinus pauses 
that produce symptoms. (Level of Evidence: C) 
2. Is indicated for symptomatic chronotropic incompetence. (Level of Evidence: C) 
3. Is indicated for symptomatic sinus bradycardia that results from required drug therapy for 
medical conditions. (Level of Evidence: C) 
Class IIa 
1. Is reasonable for SND with heart rate less than 40 bpm when a clear association between 
significant symptoms consistent with bradycardia and the actual presence of bradycardia has 
not been documented. (Level of Evidence: C) 
2. Is reasonable for syncope of unexplained origin when clinically significant abnormalities of 
sinus node function are discovered or provoked in electrophysiological studies. (Level of 
Evidence: C) 
Class IIb 
1. May be considered in minimally symptomatic patients with chronic heart rate less than 40 bpm 
while awake. (Level of Evidence: C) 
Class III 
1. Is not indicated for SND in asymptomatic patients. (Level of Evidence: C) 
2. Is not indicated for SND in patients for whom the symptoms suggestive of bradycardia have been 
clearly documented to occur in the absence of bradycardia. (Level of Evidence: C) 
3. Is not indicated for SND with symptomatic bradycardia due to nonessential drug therapy. (Level 
of Evidence: C) 
Table 1. Recommendations for permanent pacing in sinus node dysfunction7 
2.2 Hypersensitive carotid sinus syndrome 
It is defined as presyncope or syncope caused by an extreme reflex response to the 
stimulation of the carotid sinus. This hyperactive response is manifested as asystole equal or 
greater to 3 seconds, secondary to an AV block and an important decrease on systolic 
pressure. 13,14 It has two components:  
3. Cardioinhibitory: resulting from an increase in the parasympathetic tone and 
manifested by a decrease in the sinus rate or prolongation of the PR interval, an 
advanced AV block, alone or in combination.  
4. Vasopressor: conditioned by a reduction in the sympathetic activity, resulting in loss of 
vascular tone and hypotension. This effect is independent of the changes in the heart 
rate.  
For the definite diagnosis it is important to rule out other potentially fatal causes such as 
ventricular tachycardia and/or ventricular fibrillation. Ultimately, the treatment for 
symptomatic patients is permanent pacing. See Table 2 for complete recommendations. 
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Class I 
1. Is indicated for recurrent syncope caused by spontaneously occurring carotid sinus stimulation 
and carotid sinus pressure that induces ventricular asystole of more than 3 seconds. (Level of 
Evidence: C) 
Class IIa 
1. Is reasonable for syncope without clear, provocative events and with a hypersensitive 
cardioinhibitory response of 3 seconds or longer. (Level of Evidence: C) 
Class IIb 
1. May be considered for significantly symptomatic neurocardiogenic syncope associated with 
bradycardia documented spontaneously or at the time of tilt-table testing. (Level of Evidence: B) 
Class III 
1. Is not indicated for a hypersensitive cardioinhibitory response to carotid sinus stimulation 
without symptoms or with vague symptoms. (Level of Evidence: C) 
2. Is not indicated for situational vasovagal syncope in which avoidance behavior is effective and 
preferred. (Level of Evidence: C) 
Table 2. Recommendations for permanent pacing in hypersensitive carotid sinus syndrome 
and neurocardiogenic syncope7 
2.3 Acquired atrioventricular block 
Patients with abnormalities in the AV conduction can vary from asymptomatic, to having 
episodes directly related to bradycardia, ventricular arrhythmias or both. It is vitally important 
to do an adequate clinical evaluation of symptomatic patients, and of the findings in the 
different diagnostic tests available. Identifying the different degrees of AV block is mandatory 
to make a satisfactory correlation and consequently an assertive therapeutic decision, which 
historically has been demonstrated to be a permanent pacemaker when there are symptoms 
conditioned by this alteration. 15-18 See Table 3 for complete recommendations.  
The following is the classification of AV blocks:  
4. Anatomically, it is defined as supra-, intra-, or infra-His.  
5. AV block is classified as first-, second-, or third-degree (complete) block.  
a. First-degree AV block is defined as abnormal prolongation of the PR interval 
(greater than 0.20 seconds).  
b. Second-degree AV block is subclassified as type I and type II.  
i. Type I second-degree AV block is characterized by progressive prolongation of 
the interval between the onset of atrial (P wave) and ventricular (R wave) 
conduction (PR) before a nonconducted beat and is usually seen in conjunction 
with QRS. Is characterized by progressive prolongation of the PR interval 
before a nonconducted beat and a shorter PR interval after the blocked beat.  
ii. Type II second-degree AV block is characterized by fixed PR intervals before 
and after blocked beats and is usually associated with a wide QRS complex. 
When AV conduction occurs in a 2:1 pattern, block cannot be classified 
unequivocally as type I or type II, although the width of the QRS can be 
suggestive, as just described. Advanced second-degree AV block refers to the 
blocking of 2 or more consecutive P waves with some conducted beats, which 
indicates some preservation of AV conduction. In the setting of AF, a 
prolonged pause (e.g., greater than 5 seconds) should be considered to be due 
to advanced second-degree AV block.  
c. Third-degree AV block (complete heart block) is defined as absence of AV 
conduction. 
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Class I 
1. Is indicated for third-degree and advanced second-degree AV block at any anatomic level 
associated with bradycardia with symptoms (including heart failure) or ventricular arrhythmias 
presumed to be due to AV block. (Level of Evidence: C) 
2. Is indicated for third-degree and advanced second-degree AV block at any anatomic level 
associated with arrhythmias and other medical conditions that require drug therapy that result in 
symptomatic bradycardia. (Level of Evidence: C) 
3. Is indicated for third-degree and advanced second-degree AV block at any anatomic level in 
awake, symptom-free patients in sinus rhythm, with documented periods of asystole ≥3.0 seconds 
or any escape rate less than 40 bpm, or with an escape rhythm that is below the AV node. (Level 
of Evidence: C) 
4. Is indicated for third-degree and advanced second-degree AV block at any anatomic level in 
awake, symptom-free patients with AF and bradycardia with 1 or more pauses of at least 5 
seconds or longer. (Level of Evidence: C) 
5. Is indicated for third-degree and advanced second-degree AV block at any anatomic level after 
catheter ablation of the AV junction. (Level of Evidence: C) 
6. Is indicated for third-degree and advanced second-degree AV block at any anatomic level 
associated with postoperative AV block that is not expected to resolve after cardiac surgery. 
(Level of Evidence: C) 
7. Is indicated for third-degree and advanced second-degree AV block at any anatomic level 
associated with neuromuscular diseases with AV block, such as myotonic muscular dystrophy, 
Kearns-Sayre syndrome, Erb dystrophy (limb-girdle muscular dystrophy), and peroneal muscular 
atrophy, with or without symptoms. (Level of Evidence: B) 
8. Is indicated for second-degree AV block with associated symptomatic bradycardia regardless of 
type or site of block. (Level of Evidence: B) 
9. Is indicated for asymptomatic persistent third-degree AV block at any anatomic site with average 
awake ventricular rates of 40 bpm or faster if cardiomegaly or LV dysfunction is present or if the 
site of block is below the AV node. (Level of Evidence: B) 
10. Is indicated for second- or third-degree AV block during exercise in the absence of myocardial 
ischemia. (Level of Evidence: C)
Class IIa 
1. Is reasonable for persistent third-degree AV block with an escape rate greater than 40 bpm in 
asymptomatic adult patients without cardiomegaly. (Level of Evidence: C) 
2. Is reasonable for first- or second-degree AV block with symptoms similar to those of pacemaker 
syndrome or hemodynamic compromise. (Level of Evidence: B) 
3. Is reasonable for asymptomatic second-degree AV block at intra- or infra- His levels found at 
electrophysiological study. (Level of Evidence: B) 
4. Is reasonable for asymptomatic type II second-degree AV block with a narrow QRS. When type II 
second-degree AV block occurs with a wide QRS, including isolated right bundle-branch block, 
pacing becomes a Class I recommendation. (Level of Evidence: B)
Class IIb 
1. May be considered for neuromuscular diseases such as myotonic muscular dystrophy, Erb 
dystrophy, and peroneal muscular atrophy with any degree of AV block (including first-degree 
AV block), with or without symptoms, because there may be unpredictable progression of AV 
conduction disease. (Level of Evidence: B) 
2. May be considered for AV block in the setting of drug use and/or drug toxicity when the block is 
expected to recur even after the drug is withdrawn. (Level of Evidence: B)
Class III 
1. Is not indicated for asymptomatic first-degree AV block. (Level of Evidence: B) 
2. 2. Is not indicated for asymptomatic type I second-degree AV block at the supra-His (AV node) 
level or that which is not known to be intra- or infra-Hisian. (Level of Evidence: C) 
3. Is not indicated for AV block that is expected to resolve and is unlikely to recur (e.g., drug 
toxicity, Lyme disease, or transient increases in vagal tone or during hypoxia in sleep apnea 
syndrome in the absence of symptoms). (Level of Evidence: B) 
Table 3. Recommendations for acquired atrioventricular block in adults7 
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2.4 Congenital atrioventricular block 
Indications for permanent pacemaker implantation in patients under 18 year, are in general 
the same as for adults, there are only a few considerations. 1) There must be clinical correlation 
between the AV conduction alteration and the symptoms of the patient; 2) bradycardia 
 
Class I 
1. Is indicated for advanced second- or third-degree AV block associated with symptomatic 
bradycardia, ventricular dysfunction, or low cardiac output. (Level of Evidence: C) 
2. Is indicated for SND with correlation of symptoms during age-inappropriate bradycardia. The 
definition of bradycardia varies with the patient’s age and expected heart rate. (Level of Evidence: 
B)  
3. Is indicated for post-operative advanced second- or third-degree AV block that is not expected to 
resolve or that persists at least 7 days after cardiac surgery. (Level of Evidence: B) 
4. Is indicated for congenital third-degree AV block with a wide QRS escape rhythm, complex 
ventricular ectopy, or ventricular dysfunction. (Level of Evidence: B) 
5. Is indicated for congenital third-degree AV block in the infant with a ventricular rate less than 55 
bpm or with congenital heart disease and a ventricular rate less than 70 bpm. (Level of Evidence: 
C) 
Class IIa 
1. Is reasonable for patients with congenital heart disease and sinus bradycardia for the prevention 
of recurrent episodes of intra-atrial reentrant tachycardia; SND may be intrinsic or secondary to 
antiarrhythmic treatment. (Level of Evidence: C) 
2. Is reasonable for congenital third-degree AV block beyond the first year of life with an average 
heart rate less than 50 bpm, abrupt pauses in ventricular rate that are 2 or 3 times the basic cycle 
length, or associated with symptoms due to chronotropic incompetence. (Level of Evidence: B) 
3. Is reasonable for sinus bradycardia with complex congenital heart disease with a resting heart rate 
less than 40 bpm or pauses in ventricular rate longer than 3 seconds. (Level of Evidence: C) 
4. Is reasonable for patients with congenital heart disease and impaired hemodynamics due to sinus 
bradycardia or loss of AV synchrony. (Level of Evidence: C) 
5. Is reasonable for unexplained syncope in the patient with prior congenital heart surgery 
complicated by transient complete heart block with residual fascicular block after a careful 
evaluation to exclude other causes of syncope. (Level of Evidence: B)
Class IIb 
1. May be considered for transient postoperative third-degree AV block that reverts to sinus rhythm 
with residual bifascicular block. (Level of Evidence: C) 
2. May be considered for congenital third-degree AV block in asymptomatic children or adolescents 
with an acceptable rate, a narrow QRS complex, and normal ventricular function. (Level of 
Evidence: B) 
3. May be considered for asymptomatic sinus bradycardia after biventricular repair of congenital 
heart disease with a resting heart rate less than 40 bpm or pauses in ventricular rate longer than 3 
seconds. (Level of Evidence: C) 
Class III 
1. Is not indicated for transient postoperative AV block with return of normal AV conduction in the 
otherwise asymptomatic patient. (Level of Evidence: B) 
2. Is not indicated for asymptomatic bifascicular block with or without first-degree AV block after 
surgery for congenital heart disease in the absence of prior transient complete AV block. (Level of 
Evidence: C) 
3. Is not indicated for asymptomatic type I second-degree AV block. (Level of Evidence: C) 
4. Is not indicated for asymptomatic sinus bradycardia with the longest relative risk interval less 
than 3 seconds and a minimum heart rate more than 40 bpm. (Level of Evidence: C) 
Table 4. Recommendations for permanent pacing in children, adolescents, and patients with 
congenital heart disease7 
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without associated symptoms is not a justification for permanent device implantation; 3) it is 
fundamental to consider the implantation site according to the size of the device and the 
height of the patient, keeping in mind alternatives such as the epicardic. 
The most common indications for permanent pacing in this group of patients are:  
a) advanced second-degree AV block; b) third-degree AV block; c) bradycardia-tachycardia 
syndromes, and d) symptomatic sinus bradycardia.19,20 As always diagnosis should be done 
correlating clinical and tests findings. Exhaustive search of causes that could be triggering 
this disease should always be considered. See Table 4 for complete recommendations. 
2.5 Chronic bifascicular block 
Syncope is the most common manifestation in patients with bifascicular block, fortunately 
despite the recurrence, is not associated with increase on sudden death. 21,22 That cannot be 
stated for patients with third-degree AV block, in this case if they present syncope there is 
an increase in the incidence of sudden death.23 It is important to consider an 
electrophysiological study to evaluate and treat ventricular arrhythmias.24 Bifascicular block 
refers to ECG evidence of impaired conduction below the AV node in the right and left 
bundles. Alternating bundle-branch block (also known as bilateral bundle-branch block) 
refers to situations in which clear ECG evidence for block in all 3 fascicles is manifested on 
successive ECGs.  
All of these considerations oblige us to make a certain diagnosis to give the optimal 
treatment to these patients. See Table 5 for complete recommendations.  
 
Class I 
1. Is indicated for advanced second-degree AV block or intermittent third- degree AV block. (Level 
of Evidence: B) 
2. Is indicated for type II second-degree AV block. (Level of Evidence: B) 
3. Is indicated for alternating bundle-branch block. (Level of Evidence: C) 
Class IIa 
1.  Is reasonable for syncope not demonstrated to be due to AV block when other likely causes have 
been excluded specifically ventricular tachycardia. (Level of Evidence: B) 
2. Is reasonable for an incidental finding at electrophysiological study of a markedly prolonged HV 
interval (greater than or equal to 100 milliseconds) in asymptomatic patients. (Level of Evidence: 
B) 
3. Is reasonable for an incidental finding at electrophysiological study of pacing-induced infra-His 
block that is not physiological. (Level of Evidence: B) 
Class IIb 
1. May be considered in the setting of neuromuscular diseases such as myotonic muscular 
dystrophy, Erb dystrophy, and peroneal muscular atrophy with bifascicular block or any 
fascicular block, with or without symptoms. (Level of Evidence: C) 
Class III 
1. Is not indicated for fascicular block without AV block or symptoms. (Level of Evidence: B) 
2. Is not indicated for fascicular block with first-degree AV block without symptoms. (Level of 
Evidence: B) 
Table 5. Recommendations for permanent pacing in chronic bifascicular block7 
2.6 Pacing for atrioventricular block associated with Acute Myocardial Infarction 
Pharmacological and mechanical reperfusion therapies have favored decrease in the 
incidence of AV block associated to acute myocardial infarction (AMI). 25 Indications for 
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permanent pacing in patients with AMI depend on the intraventricular conduction defect, 
which does not necessarily depends on the symptoms or on the fact that the patient required 
transitory pacing. When an AV block or an intraventricular conduction block appears after 
an AMI, the localization of the AMI and the type of conduction alteration should be 
considered for permanent pacing. 26, 27 See Table 6 for complete recommendations.  
 
Class I 
1. Is indicated for persistent second-degree AV block in the His-Purkinje system with alternating 
bundle-branch block or third-degree AV block within or below the His-Purkinje system after ST-
segment elevation MI. (Level of Evidence: B) 
2. Is indicated for transient advanced second-or third-degree infranodal AV block and associated 
bundle-branch block. If the site of block is uncertain, an electrophysiological study may be 
necessary. (Level of Evidence: B) 
3. Is indicated for persistent and symptomatic second- or third-degree AV block. (Level of Evidence: 
C) 
Class IIb 
1. May be considered for persistent second- or third-degree AV block at the AV node level, even in 
the absence of symptoms. (Level of Evidence: B) 
Class III 
1. Is not indicated for transient AV block in the absence of intraventricular conduction defects. (Level 
of Evidence: B) 
2. Is not indicated for transient AV block in the presence of isolated left anterior fascicular block. 
(Level of Evidence: B) 
3. Is not indicated for new bundle-branch block or fascicular block in the absence of AV block. (Level 
of Evidence: B) 
4. Is not indicated for persistent asymptomatic first-degree AV block in the presence of bundle-
branch or fascicular block. (Level of Evidence: B) 
Table 6. Recommendations for permanent pacing after the acute phase of myocardial 
infarction7 
3. Indications for pacing in other specific conditions 
There are other specific conditions in which stimulation through pacemakers can achieve 
beneficial clinical effects, with more or less scientific evidence in its favor.  
3.1 Neurocardiogenic syncope  
Syncope can be defined as a transitory loss of conscience related with the loss of posture 
(eventually falling to the floor).  Frequently is referred as fainting, and can be the cause of 
hospitalization in 6% of patients admitted to a general hospital. Neurocardiogenic syncope is a 
frequent clinical entity in children and adults, generally associated to a benign prognosis. The 
concept known as neurally mediated syncopal syndrome can be represented by the 
hypersensitive carotid sinus syndrome, vasovagal syncope also known as neurocardiogenic 
syncope, and recently related with autonomic dysfunction and positional syncope. This is the 
origin in more than half of unexplained syncope at any age. Neurocardiogenic syncope has 
prevalence in general population of 22%28 and it is conditioned by a triggering stimulus of a 
neural autonomic reflex, usually self-limited, which conditions arterial hypotension secondary 
to peripheral vasodilatation and/or important bradycardia or transitory asystole.  
The majority of patients can be satisfactorily treated with drugs such as beta-blockers 
(atenolol), selective serotonin reuptake inhibitors (paroxetine), water retention drugs 
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(fludrocortisone) and some vasoconstrictors (midodrine) as well as dietary measures, such 
as high salt intake, exercise and lifestyle modifications. Nevertheless a small group of 
patients is affected by frequent fainting that can disturb daily living, and others can present 
episodes similar to sudden death which does not improve with the usual therapeutic 
measures. Some authors have called this type of manifestations as “malignant” 
neurocardiogenic syncope, because of recurrent falls and even physical trauma.29 Some of 
these patients can have prolonged asystole or important bradycardia during the 
neurocardiogenic syncope, that is why the placement of a pacemaker has been proposed 
and could be justified, although this is highly controversial. Various randomized trials have 
shown important reduction in the number of syncopal events in selected patients, although 
in the first studies, the patients were assigned at random to receive or not cardiac 
stimulation and this could be related to a placebo effect.30,31,32 Afterwards, in two trials the 
pacemaker was placed on all the patients and then randomized to have it “on” or “off” to 
avoid the placebo effect.  Neither study demonstrated significant difference on a 6 month 
follow up. However one of the studies showed that the most benefited patients with this 
therapeutic where those with asystole, compared to those with marked bradycardia.33,34,35 
We must remember that up to 25% of patients with neurocardiogenic syncope have a 
dominant vasodepressor component without significant bradycardia, and most likely those 
patients have the least benefit with a pacemaker. It is estimated that approximately one 
third of the patients have bradycardia or asystole as cause of syncope in the tilt-table test or 
during the spontaneous syncopal episodes. The SYMPACE trial established that the 
recurrence of syncope was prolonged even more in the patients with asystole than the 
patients with bradycardia (91 days vs. 11 days).35 Some studies demonstrated a beneficial 
effect on induced syncope during the tilt-table test.36,37  
Seventy-seven patients included in 3 studies which had syncope during the tilt-table test, 
improved substantially after placement of a dual-chamber pacemaker.38,39,40 However, other 
studies were not able to demonstrate the ability to avoid syncope, in some patients (82%) 
after placement of the pacemaker a tilt-table test was repeated and they only had 
presyncope. Thus it was possible to demonstrate that 80 to 90% of patients had marked 
symptomatic improvement reducing up to 90 to 95% the number of expected syncopal 
events.13 Three randomized controlled studies commented nevertheless, that in selected 
patients it is possible to demonstrate benefits in most of them.30,31,32 In the Second Vasovagal 
Pacemaker Study (VPS II), 100 patients were included and received a pacemaker. Then they 
were randomized to pacing with rate drop sensing, or sensing without pacing. The 
cumulative risk of syncope at 6 months was 40% for the control group and 31% for the 
actively paced group. The relative risk reduction in time to syncope with pacing was 30% (1 
p = 0.14).33 Nonetheless they concluded that pacemaker placement should not be used as a 
first line therapy in these patients.  
Although since the 90s it has been accepted by the Therapeutic Guidelines of the Cardiac 
Stimulation British Group and the AHA/ACC, the use of pacemakers for the treatment of 
severe neurocardiogenic syncope, should not be considered as first line treatment. However 
it can be considered in those patients with recurrent syncope despite optimal medical 
treatment, mainly in patients without prodromal symptoms that allow them to have 
precautions at the beginning of the episode. Also, in those in which pacing can reduce the 
frequency of syncope and/or prolong the time since the beginning of symptoms to the loss 
of conscience episode, thus facilitating necessary measures to avoid falling, like sitting or 
lying down.  
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In the other hand we must have in mind that the symptoms in the patient with 
neurocardiogenic syncope are partially secondary to bradycardia, which can be prevented by 
pacing, but greatly peripheral vasodilatation is the producing mechanism. It is important to 
stress the fact that although prolonged asystole, provoked or spontaneous, can be worrying, 
usually the prognosis is benign in those patients even without pacemaker.41  
In the patient with an intense cardioinhibitory response in the tilt-table test, placement of 
dual-chamber pacemaker can be an alternative to the medical therapy, especially in the 
highly symptomatic patient, and primarily when other therapeutic alternatives have 
failed.  
Early detection of imminent neurocardiogenic syncope by the sensing system of the 
pacemaker is an important factor when defining the best strategy of stimulation, as it is the 
optimal method of stimulation. We must remember that the drop in the heart rate is usually 
insidious and not abrupt and it is usually accompanied by peripheral vasodilatation. 
Ammirati et al compared rate drop responsiveness and rate hysteresis. They demonstrated a 
benefit for those with rate drop responsiveness (0/12 fainted) compared with rate hysteresis 
(3/8 fainted).42 Mc Leod et al compared three groups of symptomatic patients: 1) without 
pacemaker, 2) single-chamber pacemaker and, 3) dual-chamber pacemaker. They 
established that both pacing modes were equivalent, and more effective than no pacing, in 
preventing syncope. Dual-chamber pacing was superior to VVI pacing in preventing 
presyncope.43 Some authors think that high stimulating frequency (120 beat per minute), can 
be superior to standard stimulating frequency (80 beats per minute) to improve symptoms 
and avoid syncopal episodes.44  
Most of the patients with a pacemaker placed to correct the cardioinhibitory component of 
cardioneurogenic syncope, can also receive complementary medical therapy to inhibit the 
peripheral vasodilatation component. Patient-activated drug delivery systems using 
phenylephrine have been used to abort syncopal episodes with encouraging preliminary 
results.45  
We can conclude that although pacing is not the first line therapy in patients with 
neurocardiogenic syncope, in some cases in which frequency and intensity of fainting 
deteriorates quality of life, and mainly in those in which the cardioinhibitory effect during 
the tilt-table test, could benefit with placement of dual-chamber pacemaker programmed 
with a drop response algorithm with high stimulating frequencies (120 beats per minute). 
For complete recommendations see Table 2.  
3.2 Neuromuscular diseases 
In some neuromuscular diseases such as myotonic dystrophy and Emery-Dreifuss muscular 
dystrophy, some patients can develop ventricular arrhythmias and atrioventricular 
disorders which can progress to complete AV block. In these patients permanent pacing will 
possibly be required.47 Some authors have demonstrated disappearance of Stokes-Adams 
episodes through pacemaker implantation.48 In these cases the recommendations will be 
those indicated for AV block. 
3.3 Long-QT syndrome  
In patients with congenital long-QT syndrome, therapy with ß-adrenergic blockers should 
be consider the first line of treatment, will be continued for life and should be supplemented 
with implantation of a permanent pacemaker only in cases where bradycardia or AV block 
is an important characteristic of the syndrome.49 The use of oral ß-adrenergic blockers, is 
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considered the standard therapy and are usually successful in the long-term preventive 
treatment of important arrhythmias, however is has been demonstrated that in some 
patients a permanent pacing is fundamentally necessary, and even so the implantation of a 
cardioverter-defibrillator.  
It is recommendable that besides the implantation of a pacemaker, ß-Adrenergic blocker 
therapy be continued.50 Some consider that because of the availability of the cardioverter-
defibrillator with dual-chamber pacing capabilities, and given the high risk in some patients 
it could be adequate to use it as first line therapy in symptomatic patients with high risk of 
sudden death. But since cardioverter-defibrillators do not prevent torsade de pointes, these 
patients should also continue with ß-adrenergic blockers.51 See Table 7 for complete 
recommendations.  
 
Class I 
1. Is indicated for sustained pause-dependent VT, with or without QT prolongation. (Level of 
Evidence: C) 
Class IIa 
1. Is reasonable for high-risk patients with congenital long-QT syndrome. (Level of Evidence: C) 
Class IIb 
1. May be considered for prevention of symptomatic, drug-refractory, recurrent AF in patients with 
coexisting SND. (Level of Evidence: B) 
Class III 
1. Is not indicated for frequent or complex ventricular ectopic activity without sustained VT in the 
absence of the long-QT syndrome. (Level of Evidence: C)  
2. Is not indicated for torsade de pointes VT due to reversible causes. (Level of Evidence: A)  
Table 7. Recommendations for pacing to prevent tachycardia7  
3.4 Hypertrophic Obstructive Cardiomyopathy (HOCM) 
HOCM is a primary myocardial disease, characterized by asymmetric hypertrophy of the 
interventricular basal septum, conditioning reduction between the posterior wall of the left 
ventricle (LV) and the septum, leading to abnormal systolic anterior motion of the anterior 
mitral leaflet, which generates dynamic obstruction of the LV outflow tract (LVOT). This 
obstruction causes significant gradient with important symptoms, predominantly during 
effort, such as dyspnea, angina, syncope, or even sudden death. Most of the patients with 
HOCM have normal or above normal systolic LV function. It is common to find stiffness of 
the LV due to hypertrophy, conditioning considerable diastolic dysfunction that generates a 
high LV end-diastolic pressure with reduced diastolic volumes, contributing to the 
symptoms (dyspnea).  The clinical evolution is extremely variable, great proportions are 
asymptomatic, but 25% have important obstruction with abundant symptoms and bad 
prognosis. HOCM is considered the most frequent cause of effort-induced syncope or 
sudden death in people younger than 30 years.  
Treatment has the primordial purpose of reducing LVOT gradient, facilitating systolic flow 
and improving diastolic filling, which also improves symptoms. The mayor conditioners of 
LVOT obstruction are systolic septal bulging, malposition of the anterior papillary muscle, 
drag forces, and hyperdynamic LV contraction conditioning the Venturi effect. Some 
investigators have demonstrated that afterload reduction with vasodilator agents, such as 
nitroglycerin, increases the gradient, as do positive inotropic drugs like digoxin, β-agonists, 
and exercise which also has positive inotropic effect.  
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The management of patients with HOCM comprises different areas: a) activity restriction to 
avoid volume depletion, b) improvement of symptoms and quality of life, c) improvement 
of survival rate and prevention of sudden death, d) to prevent and correct complications 
(syncope and arrhythmias), and finally e) screening of relatives.  
Medical treatment has been used for chronic symptomatic HOCM patients, but in a small 
percentage (10%) of cases surgical options can be justified, if symptoms or an important 
LVOT gradient persist. Dual-chamber pacing (DDD) has been used in patients with HOCM 
without response to medical treatment.52,53,54,55 In the early 90s permanent pacing was 
proposed not only as an alternative, but as a substitute of myectomy. The principle that 
explained the beneficial effect of DDD pacing was by achieving pre stimulation of the right 
ventricle apex, that way the LV empties before the basal portion contracts and conditions 
dynamic obstruction. It requires a precise adjustment on the ventricular stimulation (AV 
interval), that way at rest or exertion the pacemaker stimulates the apex and the distal septal 
region, without compromising ventricular filling or cardiac output. It improves the gradient 
and symptoms by 25%, although in most cases improvement has been measured based on 
the patient´s perception, which in most cases is only for short periods of time. Some think 
that pacing can condition deterioration of diastolic function56, gradient decrease can be 
associated to important ventricular filling alterations and fall on the cardiac output, and 
LVOT gradient reduction can be quite modest and less than the one obtained by surgical 
myectomy.53,54 Improvement on functional ability has not been demonstrated by pacing. 
Some authors even think that the perceived improvement after the pacemaker placement 
can be a placebo effect.57,58,59,60,61  
Pacemakers have not demonstrated reduction in the risk of sudden death, nor conditions 
favourable LV remodelling. Some have suggested that DDD pacing can remodel and 
attenuate the hypertrophic septum as years goes by54, but it has not been confirmed in 
prospective studies. There are three prospective randomized studies that analyzed the 
benefits of permanent pacing in the HOCM patient, without demonstrating the clinical or 
functional benefit. In fact, in one of the patients, after 9 months the LVOT gradient was 
similar to the one before surgery.59,60  
The ACC/AHA guidelines for pacing consider it as class IIb in patients with symptomatic 
HOCM, and unresponsive to medical treatment, and class III in the patients that improve 
with β-blockers or calcium channel blockers. Even though the indications are clear, some 
studies in which the main objective is to define pacemaker utility, have included mildly 
symptomatic patients or even cases in which resting obstruction is not demonstrable, and 
only appears with provocation maneuvers59 or even with dobutamine infusion.62  
Pacemaker implantation can be influenced by: a) implantation is simple and less invasive 
compared to myocardial ablation, b) common method, most cardiologists are familiarized 
with the technique, c) commonly used drugs are employed, without side effects like 
bradycardia, d) surgical myectomy or percutaneous transluminal septal myocardial ablation 
(PTSMA) can be done at a later time, e) it can be withdrawn or inactivated at any time. A 
useful strategy can be to place a temporary pacemaker and do hemodynamic 
measurements.  If the gradient is not lowered, there will not be any benefit by placing a 
permanent pacemaker.63,64,65 Some authors think that in patients over 65 years, pacing may 
condition clinical and hemodynamic improvement60 and represents less risk than surgical 
myectomy and PTSMA. In patients with pacemakers we have the advantage of being able to 
increase β-blockers or verapamil doses, since they are protected from the deleterious effects 
like bradycardia. On the other hand, we can delay AV nodal conduction and facilitate 
synchronization and ventricular apex pre stimulation. 
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In 1995, a group of investigators placed a DDD pacemaker on a group of paediatric patients 
with non obstructive asymptomatic hypertrophic cardiomyopathy, in an attempt to interfere 
with genetic forces that later on, could develop LVOT obstruction. This was deeply 
criticized and nowadays is not considered as a therapeutic option in these patients.66,67,68  
Maron et al demonstrated in a group of patients older than 65 years, objective improvement 
of symptoms after DDD pacing. Yufu et al analyzed results in one patient, after placement of 
one apical epicardial electrode on the LV, with apparent improvement. Komsuoglu et al 
reported the case of one patient with resting LVOT gradient of 130 mmHg, that reduced to 
100 mmHg with DDD pacing with synchronized right auricular and ventricular stimulation, 
and reduced it to 20 mmHg after the placement of a biventricular pacemaker (atrial sensing 
and synchronous right and left ventricular pacing), placing percutaneously the LV electrode 
on the distal segment of the cardiac veins to have an early stimulation of the posterolateral 
LV wall. Unlike Yufu, they did not found improvement by stimulating only the LV.  
In patients with high risk of severe ventricular arrhythmias or even on survivors of sudden 
death, the use of an implantable automatic defibrillator has been recommended. Results 
have been variable in these patients. In patients with ventricular tachycardia usefulness of 
an implantable defibrillator has been analyzed. In patients with high LVOT gradient in 
which an implantable cardioverter defibrillator (ICD) is indicated, we can obtain larger 
benefit if we use the DDD or biventricular component of the ICD.  
4. Selecting the stimulation mode 
The main issues to take into account in the decision-making process to determine the 
optimal pacing mode are: the diagnosis that is causing the permanent cardiac stimulation 
indication, the need to maintain AV synchrony and the presence of chronotropic 
incompetence that demands to implant a device with rate response sensor. Other special 
features can influence the pacemaker type and the stimulation mode selection, for example: 
devices with capability to deliver atrial therapies (AF prevention or antitachycardia 
stimulation), prolonged longevity battery, automatic capture verification, etc. 
4.1 Sinus Node Dysfunction (SND) 
The algorithm in Figure 1 synthesizes the critical path in pacing mode selection for SND.  
Given the fact that in a patient with SND and normal AV conduction, the cardinal problem 
is sinus impulse generation, at least theoretically, ideal pacing mode is AAI. However, other 
methods have been studied, namely right ventricular pacing (VVI) and DDD. The current 
evidence that helps to guide the decision in this aspect is exposed in the next sections. 
4.1.1 Risk of AV block development  
An important matter is the concern about the risk of AV block in the following years after 
pacemaker implantation. In the Danish study directed by Nielsen et al, (atrial vs. dual-
chamber pacing), the incidence of symptomatic AV block after a follow-up period of 2.9 
years, was 1.9% per year.69  
4.1.2 Atrial based versus ventricular pacing protocols  
There is little information comparing atrial stimulation with other modalities. The only 
major randomized trial that included a true atrial pacing arm (AAI) compared with VVI was 
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the reported by Andersen and colleagues. They found a beneficial effect of atrial pacing 
sustained over time (8 years of follow-up), with improvement in survival, less atrial 
fibrillation, fewer thromboembolic complications, less heart failure, and a low-risk of 
atrioventricular block.70,71 
In the Danish study, when atrial pacing was compared with dual-chamber stimulation, 
DDDR pacing caused increase in left atrium diameter and AF resulted significantly less 
common during AAIR pacing.69  
Furthermore, there are few doubts about the obtained benefits by aiming to preserve the 
intrinsic ventricular activation. The MOST substudy linked the RV pacing rate with the risk 
of hospitalization due to heart failure and the probability to develop AF.72 Moreover, in the 
DAVID study (patients with implantable defibrillator), primary outcome of death or heart 
failure (HF) hospitalization was less common (13.3 vs. 22.6%) in the group that maintained 
intrinsic ventricular rhythm in comparison with patients with predominant ventricular 
paced rhythm.73  
A meta-analysis of the five main trials showed a significant reduction in the AF incidence 
and, possibly, ictus incidence, when selected pacing mode was an atrial based protocol 
(AAI/DDD) against ventricular single-chamber protocols.74 
4.1.3 Algorithms to reduce ventricular stimulation in SND 
Assuming the fact that ventricular stimulation has deleterious effects in cardiac function, 
stimulation protocols have been conceived attempting to reduce right ventricular pacing. 
Basically, there are two modalities: those who include AV interval (AVI) lengthening, and 
the minimal ventricular pacing (MVP) protocol. The first consist in programming a 
prolonged basal AV interval or an algorithm of AV hysteresis. AV hysteresis consists 
basically in a gradual lengthening of the programmed AV interval to determine if an 
intrinsic ventricular depolarization occurs within certain interval. In the MVP protocol, a 
DDDR stimulation mode changes to AAIR when spontaneous AV conduction is detected. 
When AV block occurs persistently, then AAIR mode turns into DDDR. This protocol has 
demonstrated to reduce ventricular stimulation rate in a larger proportion than other 
algorithms. In fact, the SAVEPACE trial, that included 1070 patients with dual chamber 
pacemaker, with and without MVP protocol, reported that patients without MVP showed 
99.1% of ventricular pacing, while MVP patients had 9.1%. AF incidence was 7.9% in the 
MVP group and 12.7% in the other.75  
4.1.4 Summary 
In isolated SND, in absence of AV node conduction abnormalities, seems reasonable to 
choose an atrial based stimulation mode (AAI or DDD), while programming algorithms 
favoring intrinsic ventricular activation. This approach appears to be related with a 
reduction in the incidence of AF, HF related hospitalizations, and possibly, in the occurrence 
of stroke. Moreover, since AF is not infrequent in patients with SND, is essential to implant 
a pacemaker with automatic mode switching (AMS).69-76  
4.2 Atrioventricular block 
In most patients with AV block it is desirable to maintain AV synchrony, but mainly in 
those with LV dysfunction. As has been mentioned before, single-chamber RV stimulation 
eliminates cardiac activation synchrony, with negative effects in the risk of AF, LV failure, 
www.intechopen.com
 
Clinical Applications of Pacemakers in Patients with Bradycardia and Other Specific Conditions 
 
61 
and mitral regurgitation development.69,70,71,75 That pathophysiological changes lead to 
negative clinical outcomes: increase in the incidence of death, HF hospitalizations and 
ictus.72,73,74  
On the other hand, advanced age is sometimes advocated as a reason to prefer single- 
chamber stimulation. At this point, it is noteworthy to mention that almost every main trial 
was conducted in old people (the population at higher risk of conduction disturbances).69-75  
When selecting the pacing mode in a patient with AV block, the first question to answer is if 
there is the desire to maintain the AV synchrony (if patient maintains sinus impulse 
generation and has no atrial arrhythmias precluding atrial sensing/pacing). The next aspect 
is to look for chronotropic incompetence, to evaluate the need of a rate response sensor. 
Then, one can ask if atrial stimulation is desired (for example to prevent AF or to treat 
supraventricular tachyarrhythmias).  
The algorithm in Figure 2 shows a decision tree diagram to determine pacing mode for AV 
block.  
 
 
Fig. 1. Selecting the stimulation mode in SND.  
4.3 Other indications  
Apart from patients suffering from bradyarrhythmia (for example SND and AV block), 
other pacemaker indications deserve some specific comments about programming. 
4.3.1 Neurocardiogenic syncope 
Usually, patients do not have basal bradycardia and do not need permanent cardiac 
stimulation. Pacemaker only stimulates if patient develop bradycardia or asystole as part of 
a cardioinhibitory response. Moreover, some current devices contain programmable drop 
rate response algorithms, which activates if sudden bradycardia develops. 
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4.3.2 Heart failure 
Cardiac resynchronization therapy optimal response depends on assuring a constant cardiac 
stimulation. For this reason, programming an appropriate AV delay and confirming 
ventricular pacing events (by reviewing counters and histograms) is essential. 
4.3.3 Tachyarrhythmias  
In the rare cases treated with a pacemaker, algorithms that automatically detects arrhythmia 
and applies antitachycardia pacing (ATP) exists. ATP needs to be individualized according 
to the arrhythmia rate and response to therapy. 
4.3.4 Hypertrophic cardiomyopathy (HCM) 
As in patients with heart failure, LV outflow tract gradient reduction in HCM depends on a 
constant ventricular stimulation. Attention needs to be paid in programming an appropriate 
AV delay and confirm ventricular pacing. 
 
 
Fig. 2. Selecting the stimulation mode in AV block.  
5. Device implantation techniques 
A detailed description of the implantation techniques is beyond the scope of this chapter. 
We will approach some of the more important aspects to consider when a pacemaker is to 
be implanted. 
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5.1 Patient preparation  
As in any invasive procedure, is mandatory to obtain written consent. A peripheral 
intravenous line must be placed, preferably in the arm of the planned implant side (of aid in 
case of requiring venography). Most of pacemaker implants are done in the left thoracic 
wall, mainly because of operator’s choice and comfort. Conscious sedation is optional. 
Antibiotic prophylaxis is guaranteed and is determined by local antimicrobial guidelines, 
generally with coverage for G+ and staphylococcus. In the vast majority of cases, a single 
dose of a penicillin type antibiotic (for example a cephalosporin) can be used within 2 hours 
before operation. Antibiotics like vancomicyn and gentamicin are becoming more and more 
used, particularly in patients considered at high risk of infection.  
Once in the operation room, implant area is prepared with antiseptic and delimited with 
sterile towels.77,78 
5.2 Pocket formation 
Three types of incisions are mostly used: deltopectoral, horizontal and oblique. By the time 
the incision site has been chosen, a local anesthetic is infiltrated at implantation area. In 
order to make the pacemaker pocket it should be decided if it will be subcutaneous or 
submuscular, depending on patient’s characteristics (subcutaneous tissue thickness) and the 
pulse generator size. Subcutaneous pocket is easier to make and less painful, but it is 
imperative to reach the correct layer, the prepectoral fascia. The submuscular pocket 
requires a shallow incision in the pectoralis major, then blunt dissection up to pectoralis 
minor (intramuscular) or up to ribcage, beneath pectoralis minor (subpectoral). It is painful, 
but ordinarily can be performed under conscious sedation.  
Pocket can be made before or after venous access, according to operator’s preference.77-79 
5.3 Venous access  
Venous access is more frequently obtained by one of two techniques: dissection and 
vascular incision with direct vein visualization (commonly in the cephalic vein) and by 
venous puncture (usually directed to the subclavian vein). Cephalic vein dissection has 
lower pneumothorax and lead crush risk, however, more surgical skill is required and 
difficulties to introduce more than one lead can arise. Apart from the mentioned techniques, 
another venous access sites exists, for example, axillary, internal jugular or femoral veins. 
Nevertheless, although they can be used under certain circumstances, they are not of 
rutinary choice.77-79 
5.4 Right ventricular lead placement 
Lead placement is facilitated by positioning fluoroscopy in the right anterior oblique (RAO) 
projection, which helps to define the apex of the RV. The stylet is manually curved in a 
moderate angle (this action is learned with the experience). With the curved stylet in place, 
the lead is advanced across the tricuspid valve and then out to the pulmonary artery. 
Retracting the stylet 1-2 cm usually facilitates passage to the pulmonary artery. Once in the 
pulmonary artery, the stylet is advanced again to the lead tip. Now, the electrode body is 
gently retracted up to the midpoint of the interventricular septum. The stylet is retracted 1-2 
cm and the floppy lead tip drops into the RV apex. Because the stylet is retracted, the lead 
tip is supple, precluding perforation of the RV. Adjustment of the tip position can be made 
by retracting and advancing the electrode, and, if necessary, by changing the curved one for 
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a straight stylet. Gently pulling the electrode is a reliable method to confirm that fixation of 
the lead has been achieved. This maneuver should not be performed in active fixation leads. 
Positioning an active fixation lead is similar, but once the lead tip is in the desired position, 
the helix fixation is released and the stylet removed. 77-79 
5.5 Atrial lead placement 
Essentially, there are two techniques, depending on the type of lead selected. If a preformed, 
passive fixation mechanism, “J” curve lead is utilized, the straight stylet is used to straighten 
the preformed J. In this case, after the venous access, the lead is advanced to the mid right 
atrium, and then, the stylet is withdrawn several centimeters while the lead tip gains its J 
configuration. The lead body is then slowly advanced to push it into the right atrial 
appendage, which is confirmed by fluoroscopy (in the antero-posterior projection, the tip of 
the lead will move medial to lateral with each atrial contraction).  
When a straight, active fixation lead is selected, then a preformed J stylet is used to take the 
lead tip to the desired position. Once in there, helix fixation is released and the J stylet 
removed. 77-79 
5.6 Measuring pacing and sensing thresholds 
Every time each lead is positioned and suture-fixed, pacing and sensing thresholds are 
measured to determine its correct performance. 
Table 8 summarizes the acceptable thresholds for the atrial, RV and coronary sinus (CS) 
leads. Once thresholds are measured, leads are screwed into pacemaker generator and 
pocket is sutured. 77-79 
 
 Atrial lead RV lead CS (LV) lead 
Voltage threshold <1.0 V (0.5 ms) <1.0 V (0.5 ms) <3.0 V (0.5 ms) 
P/R amplitude ≥2.0 mV ≥4.0 mV ≥5.0 mV 
Impedance 200-1000 ohm 200-1000 ohm 300-1000 ohm 
Table 8. Acceptable pacing and sensing thresholds.  
5.7 Procedure related complications 
The more frequent procedure related complications are mentioned in Table 9.80,81  
Eberhardt and colleagues reported the main factors related to procedural complications. 
They underwent a retrospective analysis of 1884 patients who received a pacemaker. The 
global complication rate was 4.5%. Complication occurrence was increased by age, reduced 
LV function, and RV dilatation. Dual-chamber system implantation led to a higher 
complication rate (6.3%) than implantation of single-chamber (2.6%) or VDD pacemakers 
(3.2%). These differences were encountered only among operators with a low or medium 
level of experience.81 
Moreover, a recent study, with a very large cohort, reported that implant related infections 
are relatively rare (192 cases/236,888 pacemaker-years, which counts for an incidence rate of 
4.82 cases/1000 pacemaker-years) after first implantation. Independent factors associated 
with an increased risk of infection were a greater number of surgical procedures (including 
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replacements), male sex, younger age, implantation during the earliest part of the study 
period, and absence of antibiotics.82  
 
Pocket complications Lead complications 
Pocket hematoma 
Infection 
Erosion  
Migration of generator 
Twiddler´s syndrome 
Generator extrusion 
Dislodgement  
Infection 
Vein thrombosis 
Air embolization 
Diaphragmatic stimulation 
CS dissection/perforation 
Myocardial perforation/tamponade 
Table 9. Pacemaker implant complications 
6. Clinical follow up for patients with pacemaker 
Follow up office visits after a pacemaker implant, varies according to each center, but in 
general, may be performed twice in the first 6 months and then once every 6-12 months. 
More commonly, patients come to pacemaker checking several times during the first year, 
and then once or twice a year after that. As elective replacement is approaching, visits 
should be more frequent. The technician and/or nurse is a very valuable allied in this 
setting, because they carry out the majority of pacemaker checks at the outpatient 
consult.83 
6.1 Main programming parameters  
A normal follow-up visit to the outpatient pacemaker clinic may take a few minutes if 
patient is asymptomatic, there are no activated alarms and main parameters are normal. 
However, as technology advances, device complexity is arising and today we have multiple 
programmable parameters. The knowledge of theses parameters and its programmability 
enables the clinician in the follow-up problem solving process.84,85  
Table 10 summarizes the main programming parameters and its possible applications. 
7. Cost-benefit in pacemakers  
Any measure oriented to optimize battery longevity will positively impact cost-efectiveness. 
Such measures may consist in improving pulse generator and leads technology or in 
optimizing pacemaker programming (above all, output voltage, pulse width and AV delay). 
In fact, reprogramming pulse generator may extend the estimated longevity by 4.25 years at 
a low cost, according to a report of Crossley et al.86 It is expected that software algorithms, 
like automatic capture verification, help in increasing battery duration.  
Obviously, dual-chamber systems are more expensive. However, considering aspects like 
quality of life is important in the evaluation of costs. Rinfret et al performed a cost-
effectiveness analysis of pacemakers in SND and concluded that dual-chamber pacing 
increases quality-adjusted life expectancy at a cost that is generally considered 
acceptable.87 
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Parameter Programmability Application 
Rate 
Increase 
Optimize cardiac output. After AV 
node RF ablation.  
Decrease 
Minimize RV pacing. Adjust rate 
below angina threshold.  
Voltage 
Increase Adapt to higher pacing threshold. 
Decrease 
Enhance battery longevity. Reduce 
extracardiac stimulation (phrenic 
nerve, pectoral muscle).  
Sensitivity 
Increase 
Correction of undersensing of P/R 
waves.  
Decrease 
Correction of oversensing (T wave, 
myopotentials). 
Refractory period 
Increase 
Atrial: minimize sensing of V far-
field potentials. 
RV: minimize sensing of A far-field 
potentials (crosstalk). 
Decrease 
Detection of early premature 
ventricular beats. 
Hysteresis  Minimize RV pacing. 
Detection/stimulation 
polarity 
Conversion to unipolar 
mode 
Optimize signal sensing. To obtain a 
more secure stimulation. 
Conversion to bipolar 
mode 
Minimize electromagnetic or 
myopotential interference. 
Elimination of extracardiac anodal 
stimulation. 
AV interval 
Increase or decrease to 
optimize LV function 
 Increase: minimize RV pacing.  
Decrease: adaptative shortening 
according to heart rate (more 
physiologic). Optimize AV 
synchrony in HF. 
PVARP Increase 
Prevent sensing of retrograde P 
waves, treatment of PMT. 
PVARP extension after a PVC On/off 
Prevent sensing of retrograde P 
waves after a PVC 
Post-atrial ventricular 
blanking period 
Increase Prevent crosstalk 
Ventricular safety pacing On/off 
Assurance of ventricular 
stimulation in the presence of 
crosstalk 
Abbreviations: AV= atrioventricular; RF= radiofrequency; RV= right ventricle; V= ventricular; LV= left 
ventricle; HF= heart failure; PVARP= post ventricular atrial refractory period; PMT= pacemaker 
mediated tachycardia; VPC= premature ventricular contraction. 
Table 10. Main programming parameters and its applications.  
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8. Future perspectives on cardiac stimulation 
There are many areas under investigation and others that need to be covered. The following 
is a selection of these areas.  
Pacemakers availability. Above all in developing countries, further efforts needs to be done to 
extend pacemaker access to all eligible population. 
Pacemakers technology. Improvements in hardware, software, battery and leads technology, 
will permit to obtain better clinical results as well as improved device performance and 
duration. 
Pacemaker indications. Clinical applications of cardiac stimulation are under extensive 
research. Aspects like biventricular or LV pacing in patients with normal systolic function or 
in congenital heart disease needs to be determined.  
Remote monitoring. This technology seems to represent a cost-effective tool to maintain an 
efficient and secure follow-up evaluation as a part of a well organized program. It is 
necessary to develop guidelines to norm its use.7   
9. Conclusion  
Permanent pacing is a therapy that can be lifesaving, established indications for main 
clinical syndromes and other specific conditions should be evaluated to offer the patient the 
best possible treatment. Once implanted determining the optimal stimulation mode is 
crucial, as it is to keep in mind all the possible complications inherent to the procedure. 
Clinical follow-up is as important as the implantation technique, to assure the patient the 
best quality of life possible.   
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